Phase 1b/2 Trial

SOUTH SAN FRANCISCO, Calif. | June 23, 2026 Calico Life Sciences has announced that the U.S. Food and Drug...

LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...

Vancouver, British Columbia | January 20, 2026 — BioVaxys Technology Corp. reported positive Phase 1B/2 clinical results from its...

ROME and BASEL, January 2026 — Nouscom has reported compelling clinical evidence supporting the potential of NOUS-209, a neoantigen-directed...